Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialisation. Under
The post Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma appeared first on Pharmaceutical Business review.